Lung cancer

Atezolizumab shows OS benefit over chemo in PD-L1 high NSCLC

Atezolizumab is a promising first line treatment option for patients with PD-L1 high NSCLC, interim OS analysis from the IMpower110 trial suggests. Presenting data at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Dr David R. Spigel from the Sarah Cannon Research Institute, Nashville, Tennessee, told delegates that the PD-L1 inhibitor demonstrated ...

Already a member?

Login to keep reading.

© 2021 the limbic